Hepatocellular carcinoma (HCC) is the third largest cause of death among all cancer cases in the world.Moreover, in most cases, it develops against the background of viral hepatitis of the liver. I should be noted, and the fact that the detection of the later stages of the forecast it usually unfavorable.This study focuses on AFP, AFP L 3, and PIVKA II as oncological markers of HCC in patients with chronic viral hepatitis. It was found that the use of the combination of PIVKA II and AFP increases the sensitivity by 16.6% compared with the use of AFP alone, which is comparable with the results of all three-tumor markers.